Tackling macular conditions through collaborative reserach
We are committed to ongoing research into age-related macular degeneration (AMD), diabetic macular oedema, macular holes, and other macular conditions that require surgery.

About us

We conduct a range of clincial trials, studies, and labratory reserach into age-related macular degeneration (AMD), diabetic macular oedema and macular holes and other conditions involving the retina, macula and vitreous fluid that require surgeries.

Our reserach group is connected with Sydney Retina and Day Surgery, which is an ophthalmic practice in central Sydney, primarily focussed on the care of patients with vitreo-retinal conditions. 

  • Associate Professor Andrew Chang
  • Dr Meidong Zhu
  • Mr Thomas Hong
  • Ms Lily Wong
  • Miss Nichole Joachim

Research highlights

We have collaborated with various research laboratories and university institutes both nationally and internationally, investigating 

Clinical trials have also been conducted on wet and try AMD and diabetic macular oedema through pharmaceutical company sponosorship.

The aim of this study is to prospectively evaluate the effectiveness of intravitreal Aflibercept for patients with exudative AMD that have responded poorly to previous anti -VEGF therapies.

The study recruited 50 patients for 24 month treatment and follow-up.

This is an observational study of patients receiving aflibercept for AMD.

Patients are given three initial loading does, then followed monthly and treated with an “as need” regime based on optical coherence tomography (OCT) and vision criteria.

The recruitment is still open.

In conjunction with Sydney Retina and Day Surgery, we are conducting a clinical trial investigating the effect of saffron on the progression of atrophic AMD.

This is a 6-month prospective, double blind, placebo controlled crossover study, with a further 12-month extension phase.

Outcomes will primarily be measured by visual acuity, flicker perimetry, electrophysiology (mfERG and pERG) and adverse event monitoring. Secondary measures include OCT, fundus autofluorescence (FAF) and retinal examination findings.

Currently 100 patients have been enrolled. The recruitment has been closed.

This is a prospective, non randomised clinical trial with 24 month treatment and follow up period.

The aim of the study is to evaluate the effectiveness of intravitreal Aflibercept in the treatment of macular oedema with central involvement secondary to diabetes that resistant to the previous treatment.

The recruitment is still open.

This study is a 12 month prospective, randomised clinical trial conducting in Sydney Eye Hospital and Sydney Retinal & Day Surgery to compare the visual, anatomy and functional outcomes in ERM surgery with or without ILM peeling.

We expect that the study results will provide further information and will help guide and standardize the surgical treatment of macular ERM; to minimize unnecessary surgical risks, as well as to help economize healthcare cost.

A donor eye program has been established at in Sydney Vitreo-Retinal Research Group in collaboration with the Lions NSW Eye Bank, providing a way for patients to bequeath their eyes for both corneal transplantation and ocular disease research purposes.

Linking histopathological findings with clinical history of patients with retinal disorders is vital to increase our understanding of these conditions.

Over 350 patients have been enrolled in this program. 14 patients had donated their eyes in the past 2 years.

This study is to systematically describe patterns of impairment of macular function in patients with focal macular disease including macular hole and epiretinal macular membrane using MAIA micro perimeter.

It will also methodically correlate macular function impairment with structural pathology identified on ocular coherence tomography (OCT) and digital fundus photography.

Associate Professor Andrew Chang

Headshot of Associate Professor Andrew Chang

Save Sight Institute

  • South Block, Sydney Eye Hospital 8 Macquarie Street Sydney NSW 2000